top partner

for CFD

What happened

Shares of Bicycle Therapeutics (NASDAQ: BCYC) were up 9% as of 1:30 p.m. ET on Monday after the healthcare stock climbed as high as 10.4% earlier in the day. The company’s shares are still down more than 8% so far this year.

So what

The clinical-stage biotech company focuses on short amino acid sequences that form stable loops called bicyclic peptides, or bicycles, to treat diseases that the company says are underserved by existing therapies. Many of the company’s therapies are being looked at to treat solid tumors. These bicyclic peptides bind with molecules with high affinity and selection, making them good drug candidates for a variety of conditions.

On Monday, the company’s shares rose when it said that, after discussions with the Food and Drug Administration (FDA), it is planning on a phase 2/3 investigational trial for BT8009 to treat metastatic bladder cancer. The trial is now expected to begin in the first quarter of 2024. The trial will have two cohorts; the first looks at the therapy in untreated bladder cancer and the second is for patients with previously treated bladder cancer.

“We are pleased to have reached alignment with the FDA on the registrational trial design, dose selection and clinical trial endpoints that could support potential accelerated approval in a broad metastatic bladder cancer population,” said Santiago Arroyo, the chief development officer at Bicycle Therapeutics.

Now what

Bicycle already has a development deal that could be worth $1.7 billion with Roche Ag. The company also has several other ongoing collaborations, including ones with Novartis, Ionis Pharmaceuticals and Bayer. In the second quarter, the company reported that it had $340.4 million in cash, not counting a $45 upfront payment from Bayer in July, or the $215.5 million it received from a public stock sale in July. The company reported a net loss of $42.6 million in the quarter, but with its strong cash position, it has plenty of time to develop its pipeline, which includes 13 other assets besides BT8009.

10 stocks we like better than Bicycle Therapeutics Plc
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now… and Bicycle Therapeutics Plc wasn’t one of them! That’s right — they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of September 11, 2023

Jim Halley has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Ionis Pharmaceuticals. The Motley Fool recommends Roche Ag. The Motley Fool has a disclosure policy.

Read the full story: Read More“>

Blog powered by G6

Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.

For any inquiries, please contact [email protected]